Positive Results for Cellectar Biosciences' Study on Potential Radiotherapy Treatment
- Wednesday, October 16, 2024
Cellectar Biosciences has announced positive results in its study evaluating iopofosine I 131, a promising radiotherapy candidate for relapsed/refractory Waldenstrom's macroglobulinemia patients. The study, which aimed to assess the effectiveness of this targeted treatment, successfully met its primary endpoint with an impressive major response rate of 61%.
The overall response rate among evaluable patients was even higher at 75.6%, with 100% of patients experiencing disease control. Notably, responses to the treatment were durable, as the median duration of response was so significant that it could not be determined. Additionally, 76% of patients remained progression-free after a median follow-up period of eight months. Even in this highly refractory WM population, the use of iopofosine monotherapy resulted in an 8% stringent complete remission (sCR).
The study was conducted as a single-arm registration study, with the goal of enrolling 50 patients. It is encouraging to see such positive outcomes in the evaluation of a potential first-in-class radiotherapy treatment for Waldenstrom's macroglobulinemia.
Moreover, iopofosine I 131 demonstrated good tolerability, with a toxicity profile consistent with Cellectar Biosciences' previously reported safety data. Notably, there were no treatment-related adverse events leading to discontinuation, and all patients recovered from cytopenias without any reported aplastic sequalae. The incidence of clinically significant bleeding events was negligible, and the rate of febrile neutropenia was minimal at just 2%. Importantly, no deaths were related to the treatment during the study.
These positive results are promising for both Cellectar Biosciences and patients diagnosed with relapsed/refractory Waldenstrom's macroglobulinemia. Further research and development in this area may lead to a groundbreaking treatment option for individuals suffering from this challenging disease.
All Rights Reserved © 2024
Post a comment